The extreme gross margin is an accounting artifact of collaboration revenue, which carries negligible cost of goods sold, but it obscures the true earning power of the business. Operating margin swung from a positive 52.2% in 2025Q3, when a one-time milestone was recognized, to -13.8% in 2026Q2, indicating that the underlying operations are heavily loss-making. Net margin of -12.7% in 2026Q2, despite the 100% gross margin, underscores that R&D and SG&A expenses consume all revenue and more, a pattern typical of a pre-commercial biotech prioritizing clinical advancement over profitability.

The persistent negative ROIC and ROE across the ten quarters, with only a brief positive spike in 2025Q3 (ROIC 9.6%) driven by the milestone, suggests that the company is in a heavy investment phase where capital is being consumed to build clinical assets. The slight improvement in ROIC from -12.1% in 2024Q4 to -10.4% in 2026Q2 may indicate that the capital base is growing faster than losses, but this is not evidence of value creation. Investors should monitor whether the MAT2A and PARG programs can translate into commercial products that eventually generate returns above the cost of capital, as the current negative returns are expected for a clinical-stage biotech.

The sharp increase in DSO to 113 days in 2026Q2, following the milestone-driven revenue in 2025Q3, indicates that a significant portion of revenue is recognized before cash is received, a common feature of collaboration agreements with milestone payments. The absence of DIO data and the minimal DPO figures (18-19 days in early 2026) suggest that the company has little inventory and limited supplier leverage, consistent with an asset-light R&D model. The cash conversion cycle cannot be fully computed due to missing DIO, but the high DSO and low DPO imply that working capital is a net use of cash, which may pressure liquidity if milestone payments are delayed.

The near-zero leverage suggests that IDEAYA is funding its operations almost entirely through equity, which reduces near-term solvency risk but exposes shareholders to dilution as the company continues to burn cash. Interest coverage is not reported, but with minimal debt, interest expense is likely immaterial; however, the lack of debt also means the company cannot rely on borrowing to bridge funding gaps. The high current ratio of 10.45 provides a comfortable liquidity buffer, but the negative operating cash flow of $163.4 million in 2026Q2 implies that the company will need to raise additional equity or secure new milestones within the next 12-18 months, based on the reported cash position of $272.6 million.

The current ratio of 10.45 and quick ratio of 10.45 indicate that IDEAYA has ample short-term assets to cover liabilities, but this is largely due to the cash raised from equity offerings and milestone payments. The absence of inventory in the quick ratio is not a concern for a biotech with no commercial products, but the rapid cash burn of $163.4 million in a single quarter suggests that the runway could be shorter than the current ratio implies. If the company fails to secure additional milestones or financing, it may face a liquidity shortfall, though the strong balance sheet provides some cushion for negotiating new partnerships.